Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278527 | 1.00 | NOTUM (0.51) | NOTUMMTNR1AMTNR1BACE | |
| SCHEMBL3365538 | 0.87 | NOTUM (0.49) | NOTUMACE | |
| SCHEMBL5847071 | 0.86 | ACE (0.54) | ACE | |
| SCHEMBL5847068 | 0.86 | ACE (0.54) | ACE | |
| SCHEMBL4278365 | 0.86 | ACE (0.54) | ACE | |
| SCHEMBL12626587 | 0.84 | XIAP (0.47) | NOTUMACE | |
| SCHEMBL8278632 | 0.83 | MTNR1A (0.55) | NOTUMMTNR1AACE | |
| SCHEMBL11890808 | 0.82 | NOTUM (0.44) | NOTUMMTNR1AMTNR1BACE | |
| SCHEMBL14610927 | 0.81 | ACE (0.47) | NOTUMACE | |
| SCHEMBL5847276 | 0.81 | DRD2 (0.48) | NOTUMMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | NOTUM 3050/4885MTNR1A 1445/4885MTNR1B 1152/4885 |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | OXTR, AVPR2, AVPR1B | NOTUM 2621/4885MTNR1A 36/4885MTNR1B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.